drugset / Trial / NCT04629495
Rapamycin - Effects on Alzheimer's and Cognitive Health
Phase 2
Active not recruiting
40 enrolled
The University of Texas Health Science Center at San Antonio
Alzheimer's Association · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Timeline
- Start
- 2021-08-11
- Primary completion
- 2026-03-05
- Completion
- 2027-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sirolimus | Small molecule | 1 mg | Oral |